Acurx Pharmaceuticals
NASDAQ: ACXPStaten Island, US · Founded 2017 · Delaware corporation · 1 known investors
Find your way into Acurx Pharmaceuticals
153 people in our graph share verified history with the Acurx Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.
Patch Paczkowskiunlockedknows David Luci · together at Albany Law School (overlapped)
knows the team · via Ernst & Young LLP
×10knows the team · via Bucknell University
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics targeting bacterial infections classified as priority pathogens by the WHO, CDC, and FDA. It is a publicly held company focused on antibiotic drug development.
Founders & leadership
Acurx Pharmaceuticals was founded in 2017 by Robert J. DeLuccia, David Luci, and David P. Luci.
RJ
Robert J. DeLucciaCo-founder
DL
David LuciinFounderDavid Luci is co-founder, President, and CEO of Acurx Pharmaceuticals (NASDAQ: ACXP), a clinical-stage biopharmaceutical company developing new antibiotics for priority bacterial pathogens. He previously served as President and CEO of Dipexium Pharmaceuticals, held executive and board positions at Abeona Therapeutics and MacroChem, and worked in healthcare at Bioenvision Inc.; earlier in his career he was a CPA at Ernst & Whinney and practiced healthcare law at Paul Hastings, covering mergers and acquisitions and corporate finance.
DP
David P. LuciinPresident, Chief Executive Officer and DirectorDavid P. Luci is co-founder, President, and CEO of Acurx Pharmaceuticals, a clinical-stage biopharmaceutical company developing antibiotics for priority pathogens. He previously served as President and CEO of Dipexium Pharmaceuticals until its merger with PLx Pharma, and held executive roles at MacroChem and Bioenvision; earlier in his career, he worked as a CPA at Ernst & Whinney and as a corporate lawyer at Paul Hastings, focusing on healthcare transactions.
RG
Robert G. ShawahinExecutive
Board
JS
Joseph ScodariBoard director
CS
Carl SailerBoard director
JD
James DonohueBoard director
JH
Jack H. DeanBoard director
TH
Thomas HarrisonBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$22.6M disclosed across 6 of 7 rounds · 2018–2026
▶$4.6MraisedApr 2026 · 5 investors · PharmaceuticalsRule 506(b)
▶$4.6MraisedApr 2026 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jack H. DeanDirector
- James DonohueDirector
- Thomas HarrisonDirector
- Robert J. DeLucciaExecutive Officer, Director
- Joseph ScodariDirector
- Carl SailerDirector
- Robert G. ShawahExecutive Officer
- David P. LuciExecutive Officer, Director
- Offering amount
- $4.6M
- Amount sold
- $4.6M
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedJun 2025 · 1 investors · PharmaceuticalsRule 506(b)
▶$4MraisedJun 2025 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- ROBERT G. SHAWAHExecutive Officer
- JAMES DONOHUEDirector
- CARL SAILERDirector
- JOSEPH SCODARIDirector
- ROBERT J. DELUCCIAExecutive Officer, Director
- THOMAS HARRISONDirector
- JACK H. DEANDirector
- DAVID P. LUCIExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $4M
- Sales commissions
- $186.7K
- Placement agents
- H.C. WAINWRIGHT & CO., LLC
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12MofferedMay 2025 · 1 investors · PharmaceuticalsRule 506(b)
▶$12MofferedMay 2025 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jack H. DeanDirector
- David P. LuciExecutive Officer
- James DonohueDirector
- Joseph ScodariDirector
- Thomas HarrisonDirector
- Robert J. DeLucciaExecutive Officer, Director
- Robert G. ShawahExecutive Officer
- Carl SailerDirector
- Offering amount
- $12M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.4MraisedMar 2025 · 6 investors · PharmaceuticalsRule 506(b)
▶$3.4MraisedMar 2025 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert G. ShawahExecutive Officer
- Jack H. DeanDirector
- Joseph ScodariDirector
- James DonohueDirector
- Carl SailerDirector
- Robert J. DeLucciaExecutive Officer, Director
- Thomas HarrisonDirector
- David P. LuciExecutive Officer
- Offering amount
- $3.4M
- Amount sold
- $3.4M
- Sales commissions
- $117.8K
- Finders' fees
- $117.8K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedJan 2025 · 12 investors · PharmaceuticalsRule 506(b)
▶$2.4MraisedJan 2025 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joseph ScodariDirector
- Carl SailerDirector
- James DonohueDirector
- Robert G. ShawahExecutive Officer
- Robert J. DeLucciaExecutive Officer, Director
- Jack H. DeanDirector
- Thomas HarrisonDirector
- David P. LuciExecutive Officer
- Offering amount
- $2.4M
- Amount sold
- $2.4M
- Sales commissions
- $163.1K
- Finders' fees
- $110K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$455KraisedJan 2020 · 21 investors · BiotechnologyRule 506(b)
▶$455KraisedJan 2020 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert G. ShawahExecutive Officer
- Carl SailerDirector
- Anthony JadhonDirector
- Paul BaehrDirector
- Mark RathjenDirector
- David P. LuciExecutive Officer, Director
- Robert J. DeLucciaExecutive Officer, Director
- Michael DuffyDirector
- John TerranaDirector
- Katie JadhonDirector
- Offering amount
- $6M
- Amount sold
- $455K
- First sale
- Jan 2020
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
▶$7.8MraisedOct 2019 · 202 investors · BiotechnologyRule 506(b)
▶$7.8MraisedOct 2019 · 202 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David P. LuciDirector
- Robert J. DeLucciaDirector
- Robert G. ShawahExecutive Officer
- Offering amount
- $7.8M
- Amount sold
- $7.8M
- First sale
- Mar 2018
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$57.2Mvaluation at IPOJun 2021 · $6.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 2
by search overlap
Robinhood32 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
TradingView22 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Companies competing with Acurx Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update - AOLaol.com · Aug 2026Frequently asked questions
- What does Acurx Pharmaceuticals do?
- Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics targeting bacterial infections classified as priority pathogens by the WHO, CDC, and FDA. It is a publicly held company focused on antibiotic drug development.
- Who founded Acurx Pharmaceuticals?
- Acurx Pharmaceuticals was founded by Robert J. DeLuccia, David Luci, David P. Luci in 2017.
- Who are Acurx Pharmaceuticals's investors?
- Acurx Pharmaceuticals's investors include CANTILEVER INVESTORS.
- How much funding has Acurx Pharmaceuticals raised?
- Acurx Pharmaceuticals has disclosed $22.6M raised across 6 of its 7 known rounds.
- Where is Acurx Pharmaceuticals headquartered?
- Acurx Pharmaceuticals is headquartered in Staten Island, US.